223 related articles for article (PubMed ID: 24454895)
1. A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity.
Leigh ND; Bian G; Ding X; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
PLoS One; 2014; 9(1):e85587. PubMed ID: 24454895
[TBL] [Abstract][Full Text] [Related]
2. A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.
Ding X; Bian G; Leigh ND; Qiu J; McCarthy PL; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
J Immunol; 2012 Nov; 189(10):4719-27. PubMed ID: 23045613
[TBL] [Abstract][Full Text] [Related]
3. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.
Burdelya LG; Brackett CM; Kojouharov B; Gitlin II; Leonova KI; Gleiberman AS; Aygun-Sunar S; Veith J; Johnson C; Haderski GJ; Stanhope-Baker P; Allamaneni S; Skitzki J; Zeng M; Martsen E; Medvedev A; Scheblyakov D; Artemicheva NM; Logunov DY; Gintsburg AL; Naroditsky BS; Makarov SS; Gudkov AV
Proc Natl Acad Sci U S A; 2013 May; 110(20):E1857-66. PubMed ID: 23630282
[TBL] [Abstract][Full Text] [Related]
4. Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice.
Hossain MS; Ramachandiran S; Gewirtz AT; Waller EK
PLoS One; 2014; 9(5):e96165. PubMed ID: 24879439
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy.
Burdelya LG; Gleiberman AS; Toshkov I; Aygun-Sunar S; Bapardekar M; Manderscheid-Kern P; Bellnier D; Krivokrysenko VI; Feinstein E; Gudkov AV
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):228-34. PubMed ID: 22000579
[TBL] [Abstract][Full Text] [Related]
6. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
[TBL] [Abstract][Full Text] [Related]
7. CBLB502, a Toll-like receptor 5 agonist, offers protection against radiation-induced male reproductive system damage in mice.
Bai H; Sun F; Yang G; Wang L; Zhang Q; Zhang Q; Zhan Y; Chen J; Yu M; Li C; Yin R; Yang X; Ge C
Biol Reprod; 2019 Jan; 100(1):281-291. PubMed ID: 30084935
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 5 agonist CBLB502 induces radioprotective effects in vitro.
Shi T; Li L; Zhou G; Wang C; Chen X; Zhang R; Xu J; Lu X; Jiang H; Chen J
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):487-495. PubMed ID: 28407032
[TBL] [Abstract][Full Text] [Related]
9. The role of TRIF protein in regulating the proliferation and antigen presentation ability of myeloid dendritic cells through the ERK1/2 signaling pathway in chronic low-grade inflammation of intestinal mucosa mediated by flagellin-TLR5 complex signal.
Zhuang Z; Chen Y; Zheng J; Chen S
PeerJ; 2024; 12():e16716. PubMed ID: 38188180
[TBL] [Abstract][Full Text] [Related]
10. NLRC4 Mutation in flagellin-derived peptide CBLB502 ligand-binding domain reduces the inflammatory response but not radioprotective activity.
Lai L; Yang G; Yao X; Wang L; Zhan Y; Yu M; Yin R; Li C; Yang X; Ge C
J Radiat Res; 2019 Nov; 60(6):780-785. PubMed ID: 31599956
[TBL] [Abstract][Full Text] [Related]
11. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.
Yang H; Brackett CM; Morales-Tirado VM; Li Z; Zhang Q; Wilson MW; Benjamin C; Harris W; Waller EK; Gudkov AV; Burdelya LG; Grossniklaus HE
Oncotarget; 2016 Jan; 7(3):2936-50. PubMed ID: 26655090
[TBL] [Abstract][Full Text] [Related]
12. CBLB502, an agonist of Toll-like receptor 5, has antioxidant and scavenging free radicals activities in vitro.
Li W; Ge C; Yang L; Wang R; Lu Y; Gao Y; Li Z; Wu Y; Zheng X; Wang Z; Zhang C
Int J Biol Macromol; 2016 Jan; 82():97-103. PubMed ID: 26476243
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 5 signaling restrains T-cell/natural killer T-cell activation and protects against concanavalin A-induced hepatic injury.
Wang L; Zhang W; Ge CH; Yin RH; Xiao Y; Zhan YQ; Yu M; Li CY; Ge ZQ; Yang XM
Hepatology; 2017 Jun; 65(6):2059-2073. PubMed ID: 28273362
[TBL] [Abstract][Full Text] [Related]
14. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models.
Burdelya LG; Krivokrysenko VI; Tallant TC; Strom E; Gleiberman AS; Gupta D; Kurnasov OV; Fort FL; Osterman AL; Didonato JA; Feinstein E; Gudkov AV
Science; 2008 Apr; 320(5873):226-30. PubMed ID: 18403709
[TBL] [Abstract][Full Text] [Related]
15. Activated human neonatal CD8+ T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation.
McCarron M; Reen DJ
J Immunol; 2009 Jan; 182(1):55-62. PubMed ID: 19109135
[TBL] [Abstract][Full Text] [Related]
16. Indirect Toll-like receptor 5-mediated activation of conventional dendritic cells promotes the mucosal adjuvant activity of flagellin in the respiratory tract.
Fougeron D; Van Maele L; Songhet P; Cayet D; Hot D; Van Rooijen N; Mollenkopf HJ; Hardt WD; Benecke AG; Sirard JC
Vaccine; 2015 Jun; 33(29):3331-41. PubMed ID: 26003491
[TBL] [Abstract][Full Text] [Related]
17. A TLR5 agonist inhibits acute renal ischemic failure.
Fukuzawa N; Petro M; Baldwin WM; Gudkov AV; Fairchild RL
J Immunol; 2011 Oct; 187(7):3831-9. PubMed ID: 21890657
[TBL] [Abstract][Full Text] [Related]
18. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
Brackett CM; Kojouharov B; Veith J; Greene KF; Burdelya LG; Gollnick SO; Abrams SI; Gudkov AV
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E874-83. PubMed ID: 26831100
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer.
Rhee SH; Im E; Pothoulakis C
Gastroenterology; 2008 Aug; 135(2):518-28. PubMed ID: 18538140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
